Biotechnology companies are making strides in developing innovative combination therapies to combat challenging cancers, attracting attention from investors. AIM ImmunoTech Inc. is at the forefront of this movement, with its stock experiencing a significant surge following a promising mid-year update on the DURIPANC Phase 2 study. Collaborating with AstraZeneca and Erasmus Medical Center, the study focuses on evaluating Ampligen in combination with AstraZeneca’s Imfinzi in metastatic pancreatic cancer patients.
With 14 subjects enrolled thus far, the study aims to determine the clinical benefit rate of the combination therapy, while also exploring factors such as overall survival, progression-free survival, and immune monitoring using tissue biopsies and peripheral profiling. The mid-year report has shown encouraging results, indicating no significant toxicity and superior PFS and OS compared to traditional maintenance or second-line immunotherapies. AIM’s strategic intellectual property plan, including a U.S. patent extension for Ampligen as an oncology treatment, further solidifies its position in the field. As a result, AIM ImmunoTech shares have surged by 36.79% to $11.49, reflecting the growing optimism surrounding the company’s innovative approach to cancer treatment.
Read more from benzinga.com